EZH2 and lymphoma: Interestingly, SUDLH8 is more sensitive to HKMTI-1-005 than the other lymphoma lines with WT EZH2 (Table 3), suggesting that increased sensitivity to this dual inhibitor will not be dependent on cancer cells carrying activating mutations but perhaps any mechanism of increased dependency on EZH2.